TAP Appoints New Non-Executive Director To Strengthen TAP’s Management Team in the Field of Cell Based Therapeutics
News Jan 14, 2011
Vogt’s extensive experience in directing the commercial and operating strategy of major life science companies will allow TAP to continue its developments of automated systems in fields such as cell based therapeutics and regenerative medicine.
Vogt has had an impressive career in general management, marketing, sales, product management and finance in the life science market sector. She is currently President and Chief Executive Officer of SeraCare Life Sciences Inc, a provider of products and services for discovery, development and production of human diagnostics and therapeutics. She also serves as a Non-Executive Director on the board of life science equipment manufacturer, Andor Technology.
For the past four years, Vogt has been responsible for directing SeraCare’s commercial and operating strategy and has been credited with successfully turning the company around in 2006, leading to a notable period of sustained growth and profitability. Prior to this, Susan held a variety of senior management positions within multinational bioscience company, Millipore. From 2001 to 2005 she served as a Corporate Officer and President of their BioPharmaceutical Division, where she successfully ran a $520 million division with more than 1,600 employees. Her commercial experience is supported by a BA from Brown University and an MBA from Boston University.
Susan Vogt, TAP’s new Non-Executive Director stated: “TAP is a progressive company with an established reputation for introducing truly innovative cell processing products to the life science market. I’m delighted to be working with TAP’s senior management team, to offer them counsel on strategies for growing and increasing the profitability of their portfolio in exciting fields such as regenerative medicine.”
David Newble, CEO at TAP continued: “Susan is well-known and respected in the life science industry, and we are pleased to welcome her to TAP’s Board of Non-Executive Directors. Susan will bring a fresh perspective and additional industry experience to the Board, and we look forward to having her input as TAP continues to develop and commercialise automated systems for cell bioprocessing, manufacture of cell therapies and cell based testing.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
3rd Annual DIGI-TECH PHARMA 2019 Conference & Expo
May 21 - May 22, 2019